-
1
-
-
33746969954
-
Clinical management of women with metastatic breast cancer: A descriptive study according to age group
-
Manders K,van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 2006;6:179.
-
(2006)
BMC Cancer
, vol.6
, pp. 179
-
-
Manders, K.1
van de Poll-Franse, L.V.2
Creemers, G.J.3
Vreugdenhil, G.4
van der Sangen, M.J.5
Nieuwenhuijzen, G.A.6
-
2
-
-
0029759541
-
Annual hazard rates of recurrence for breast cancer after primary therapy
-
Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2738-2746
-
-
Saphner, T.1
Tormey, D.C.2
Gray, R.3
-
3
-
-
0034097586
-
Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis
-
Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59: 271-8.
-
(2000)
Breast Cancer Res Treat
, vol.59
, pp. 271-278
-
-
Solomayer, E.F.1
Diel, I.J.2
Meyberg, G.C.3
Gollan, C.4
Bastert, G.5
-
4
-
-
84928099132
-
Surveillance of patients following primary therapy
-
In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors, 4th ed. Philadelphia: Lippincott Wil&Wilkins
-
Robert WC. Surveillance of patients following primary therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Disease of the breast. 4th ed. Philadelphia: Lippincott Wil&Wilkins; 2009. p.823-31.
-
(2009)
Disease of the Breast
, pp. 823-831
-
-
Robert, W.C.1
-
5
-
-
0022535311
-
Metastatic breast cancer confined to the skeletal system. An indolent disease
-
Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986;81:381-6.
-
(1986)
Am J Med
, vol.81
, pp. 381-386
-
-
Sherry, M.M.1
Greco, F.A.2
Johnson, D.H.3
Hainsworth, J.D.4
-
6
-
-
0022860180
-
Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy
-
Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58:2589-93.
-
(1986)
Cancer
, vol.58
, pp. 2589-2593
-
-
Scheid, V.1
Buzdar, A.U.2
Smith, T.L.3
Hortobagyi, G.N.4
-
7
-
-
0034051908
-
Risk of complications from bone metastases in breast cancer. Implications for management
-
Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 2000;36:476-82.
-
(2000)
Eur J Cancer
, vol.36
, pp. 476-482
-
-
Plunkett, T.A.1
Smith, P.2
Rubens, R.D.3
-
8
-
-
0034661681
-
Predictors of skeletal complications in patients with metastatic breast carcinoma
-
Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89:363-8.
-
(2000)
Cancer
, vol.89
, pp. 363-368
-
-
Domchek, S.M.1
Younger, J.2
Finkelstein, D.M.3
Seiden, M.V.4
-
9
-
-
0031964897
-
Clinical course and prognostic factors following bone recurrence from breast cancer
-
Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;77:336-40.
-
(1998)
Br J Cancer
, vol.77
, pp. 336-340
-
-
Coleman, R.E.1
Smith, P.2
Rubens, R.D.3
-
10
-
-
79952609466
-
Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: A single-institution retrospective analysis
-
Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist 2011;16:155-64.
-
(2011)
Oncologist
, vol.16
, pp. 155-164
-
-
Niikura, N.1
Liu, J.2
Hayashi, N.3
Palla, S.L.4
Tokuda, Y.5
Hortobagyi, G.N.6
-
11
-
-
0037301972
-
Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor
-
Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003; 97:545-53.
-
(2003)
Cancer
, vol.97
, pp. 545-553
-
-
Chang, J.1
Clark, G.M.2
Allred, D.C.3
Mohsin, S.4
Chamness, G.5
Elledge, R.M.6
-
12
-
-
0041508749
-
Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients
-
Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14:1234-40.
-
(2003)
Ann Oncol
, vol.14
, pp. 1234-1240
-
-
Koizumi, M.1
Yoshimoto, M.2
Kasumi, F.3
Ogata, E.4
-
13
-
-
0043236248
-
Bone metastases from breast carcinoma: Histopathologicalradiological correlations and prognostic features
-
James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, et al. Bone metastases from breast carcinoma: histopathologicalradiological correlations and prognostic features. Br J Cancer 2003;89:660-5.
-
(2003)
Br J Cancer
, vol.89
, pp. 660-665
-
-
James, J.J.1
Evans, A.J.2
Pinder, S.E.3
Gutteridge, E.4
Cheung, K.L.5
Chan, S.6
-
14
-
-
84859645793
-
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases
-
Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 2012;118:2039-47.
-
(2012)
Cancer
, vol.118
, pp. 2039-2047
-
-
Niikura, N.1
Liu, J.2
Hayashi, N.3
Palla, S.L.4
Tokuda, Y.5
Hortobagyi, G.N.6
-
15
-
-
0034554804
-
Identifying breast cancer patients at high risk for bone metastases
-
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000;18:3925-35.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3925-3935
-
-
Colleoni, M.1
O'Neill, A.2
Goldhirsch, A.3
Gelber, R.D.4
Bonetti, M.5
Thürlimann, B.6
-
16
-
-
0023145358
-
Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients
-
Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
-
(1987)
J Clin Oncol
, vol.5
, pp. 55-61
-
-
Clark, G.M.1
Sledge Jr., G.W.2
Osborne, C.K.3
McGuire, W.L.4
-
17
-
-
0021349054
-
Steroid-hormone receptors and survival after first relapse in breast cancer
-
Howell A, Barnes DM, Harland RN, Redford J, Bramwell VH, Wilkinson MJ, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984;1:588-91.
-
(1984)
Lancet
, vol.1
, pp. 588-591
-
-
Howell, A.1
Barnes, D.M.2
Harland, R.N.3
Redford, J.4
Bramwell, V.H.5
Wilkinson, M.J.6
-
18
-
-
0032189117
-
Treatment of breast cancer
-
Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
-
(1998)
N Engl J Med
, vol.339
, pp. 974-984
-
-
Hortobagyi, G.N.1
-
19
-
-
0023858669
-
Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognoses
-
Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 1988;6:89-97.
-
(1988)
J Clin Oncol
, vol.6
, pp. 89-97
-
-
Goldhirsch, A.1
Gelber, R.D.2
Castiglione, M.3
-
20
-
-
0036710434
-
Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women
-
Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjövall M, Fornander T, et al. Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. Eur J Cancer 2002;38:1860-70.
-
(2002)
Eur J Cancer
, vol.38
, pp. 1860-1870
-
-
Fredriksson, I.1
Liljegren, G.2
Arnesson, L.G.3
Emdin, S.O.4
Palm-Sjövall, M.5
Fornander, T.6
-
21
-
-
0034162528
-
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
-
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
-
(2000)
Cancer
, vol.88
, pp. 1082-1090
-
-
Lipton, A.1
Theriault, R.L.2
Hortobagyi, G.N.3
Simeone, J.4
Knight, R.D.5
Mellars, K.6
-
22
-
-
0033050818
-
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
-
Protocol 18 Aredia Breast Cancer Study Group
-
Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
-
(1999)
J Clin Oncol
, vol.17
, pp. 846-854
-
-
Theriault, R.L.1
Lipton, A.2
Hortobagyi, G.N.3
Leff, R.4
Glück, S.5
Stewart, J.F.6
-
23
-
-
10544228130
-
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
-
Protocol 19 Aredia Breast Cancer Study Group
-
Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
-
(1996)
N Engl J Med
, vol.335
, pp. 1785-1791
-
-
Hortobagyi, G.N.1
Theriault, R.L.2
Porter, L.3
Blayney, D.4
Lipton, A.5
Sinoff, C.6
-
24
-
-
7144223389
-
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
-
Protocol 19 Aredia Breast Cancer Study Group
-
Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2038-2044
-
-
Hortobagyi, G.N.1
Theriault, R.L.2
Lipton, A.3
Porter, L.4
Blayney, D.5
Sinoff, C.6
-
25
-
-
10744233992
-
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
-
Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
-
(2004)
Cancer
, vol.100
, pp. 36-43
-
-
Rosen, L.S.1
Gordon, D.H.2
Dugan Jr., W.3
Major, P.4
Eisenberg, P.D.5
Provencher, L.6
-
26
-
-
0042914647
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
-
Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3150-3157
-
-
Rosen, L.S.1
Gordon, D.2
Tchekmedyian, S.3
Yanagihara, R.4
Hirsh, V.5
Krzakowski, M.6
-
27
-
-
0035463593
-
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
-
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
-
(2001)
Cancer J
, vol.7
, pp. 377-387
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
Howell, A.4
Belch, A.5
Mackey, J.6
-
28
-
-
10744233021
-
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
-
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
-
(2003)
Cancer
, vol.98
, pp. 1735-1744
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
Howell, A.4
Belch, A.5
Mackey, J.6
-
29
-
-
10744227993
-
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
-
Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2893-2897
-
-
Santini, D.1
Vincenzi, B.2
Dicuonzo, G.3
Avvisati, G.4
Massacesi, C.5
Battistoni, F.6
-
30
-
-
0035917560
-
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
-
Jagdev SP, Coleman RE, Shipman CM, Rostami H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34.
-
(2001)
Br J Cancer
, vol.84
, pp. 1126-1134
-
-
Jagdev, S.P.1
Coleman, R.E.2
Shipman, C.M.3
Rostami, H.A.4
Croucher, P.I.5
-
31
-
-
33646107396
-
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro
-
Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92-103.
-
(2006)
Tumour Biol
, vol.27
, pp. 92-103
-
-
Neville-Webbe, H.L.1
Evans, C.A.2
Coleman, R.E.3
Holen, I.4
-
32
-
-
51049114468
-
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer
-
Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 1167-1178
-
-
Ottewell, P.D.1
Mönkkönen, H.2
Jones, M.3
Lefley, D.V.4
Coleman, R.E.5
Holen, I.6
-
33
-
-
56749165071
-
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up
-
Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007-11.
-
(2008)
Ann Oncol
, vol.19
, pp. 2007-2011
-
-
Diel, I.J.1
Jaschke, A.2
Solomayer, E.F.3
Gollan, C.4
Bastert, G.5
Sohn, C.6
-
34
-
-
9444254706
-
Ten-year fol-low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
-
Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year fol-low-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004;43:650-6.
-
(2004)
Acta Oncol
, vol.43
, pp. 650-656
-
-
Saarto, T.1
Vehmanen, L.2
Virkkunen, P.3
Blomqvist, C.4
-
35
-
-
77954580167
-
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
-
Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188-94.
-
(2010)
Ann Oncol
, vol.21
, pp. 2188-2194
-
-
Eidtmann, H.1
de Boer, R.2
Bundred, N.3
Llombart-Cussac, A.4
Davidson, N.5
Neven, P.6
-
36
-
-
84655169571
-
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
-
Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012;48:187-95.
-
(2012)
Eur J Cancer
, vol.48
, pp. 187-195
-
-
Yan, T.1
Yin, W.2
Zhou, Q.3
Zhou, L.4
Jiang, Y.5
Du, Y.6
-
37
-
-
80054035939
-
Breast-cancer adjuvant therapy with zoledronic acid
-
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
-
(2011)
N Engl J Med
, vol.365
, pp. 1396-1405
-
-
Coleman, R.E.1
Marshall, H.2
Cameron, D.3
Dodwell, D.4
Burkinshaw, R.5
Keane, M.6
-
38
-
-
60549097419
-
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
-
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:67991.
-
(2009)
N Engl J Med
, vol.360
, pp. 67991
-
-
Gnant, M.1
Mlineritsch, B.2
Schippinger, W.3
Luschin-Ebengreuth, G.4
Pöstlberger, S.5
Menzel, C.6
-
39
-
-
67649818458
-
Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases
-
Park IH, Ro J, Nam BH, Kwon Y, Lee KS. Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer 2009;9:154.
-
(2009)
BMC Cancer
, vol.9
, pp. 154
-
-
Park, I.H.1
Ro, J.2
Nam, B.H.3
Kwon, Y.4
Lee, K.S.5
|